Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

This study uses protein analysis (proteomics) to guide and personalize the selection of immune checkpoint-based treatments for patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). Rather than giving everyone the same treatment, this approach uses detailed protein profiling to determine which combination may work best for each individual. **You may be eligible if...** - You are 18 or older - You have confirmed advanced (stage IIIC or IV) non-small cell lung cancer that cannot be surgically removed - You are a good candidate for standard immune checkpoint inhibitor-based therapy - You have not yet received treatment for metastatic disease (prior early-stage treatment is acceptable if finished more than 80 days ago) **You may NOT be eligible if...** - Your tumor has certain genetic mutations (in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1) that would direct you to a targeted therapy instead - You have health conditions that prevent the safe use of immune checkpoint drugs - You have already received systemic treatment for stage IIIC or IV lung cancer Talk to your doctor to see if this trial is right for you.